(Total Views: 318)
Posted On: 11/14/2017 3:17:25 PM
Post# of 15624
NOTE 4 - SUBSEQUENT EVENTS
In October 2017, the Company initiated a Phase I safety study at Sheba,blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers.
In October 2017, the Company initiated a Phase I safety study at Sheba,blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers.
(0)
(0)Scroll down for more posts ▼
